FLT3 and acute myeloid leukemia: In a recent subgroup analysis, the COG phase 3 trial AAML0531 reported decreased relapse rates in children with FLT3–ITD AML with addition of the CD33-targeting antibody-drug conjugate gemtuzumab ozogamicin to standard chemotherapy (16, 34), demonstrating potential for improved clinical outcomes in this high-risk patient population with inclusion of targeted therapies.